Who is sponsoring NCT02064725?

NCT02064725 is sponsored by Kevelt AS.

What drugs are being tested in NCT02064725?

Interventions in NCT02064725: Sodium cridanimod.

What condition does NCT02064725 study?

NCT02064725 studies Recurrent or Persistent Endometrial Carcinoma.

Is NCT02064725 still recruiting?

NCT02064725 is currently status unknown. Last updated 23 January 2017.

Last reviewed 2017-01-23 · How we verify

NCT02064725

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma

Status unknown Phase 2 Last updated 23 January 2017

What this trial tests

Phase 2 trial testing Sodium cridanimod in Recurrent or Persistent Endometrial Carcinoma in 8 participants. Status unknown.

Timeline

1 September 2014

Primary endpoint
1 January 2018

1 July 2018

Quick facts

Lead sponsor	Kevelt AS
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	1 September 2014
Primary completion	1 January 2018
Estimated completion	1 July 2018
Sites	21 locations across United States, Belarus, Czechia, Slovakia, Ukraine

Drugs / interventions tested

Sodium cridanimod — full drug profile →

Conditions studied

Recurrent or Persistent Endometrial Carcinoma — all drugs for Recurrent or Persistent Endometrial Carcinoma →

Sponsor

Kevelt AS

Who can join

18 and older, female only, with Recurrent or Persistent Endometrial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Objective Response Rate
Time frame: 12 months

Sponsor's own description

This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent PrR-negative endometrial cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma.
Lv M, Chen P, Bai M, Huang Y, et al · · 2022 · cited 17× · PMID 36551694 · DOI 10.3390/cancers14246210

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02064725 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kevelt AS
Last refreshed: 23 January 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02064725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing